Abstract

BackgroundOsteosarcoma (OS) metastasis is the most common cause of cancer-related mortality, however, no sufficient clinical biomarkers have been identified. In this study, we identified five genes to help predict metastasis at diagnosis.MethodsWe performed weighted gene co-expression network analysis (WGCNA) to identify the most relevant gene modules associated with OS metastasis. An important machine learning algorithm, the support vector machine (SVM), was employed to predict key genes for classifying the OS metastasis phenotype. Finally, we investigated the clinical significance of key genes and their enriched pathways.ResultsEighteen modules were identified in WGCNA, among which the pink, red, brown, blue, and turquoise modules demonstrated good preservation. In the five modules, the brown and red modules were highly correlated with OS metastasis. Genes in the two modules closely interacted in protein–protein interaction networks and were therefore chosen for further analysis. Genes in the two modules were primarily enriched in the biological processes associated with tumorigenesis and development. Furthermore, 65 differentially expressed genes were identified as common hub genes in both WGCNA and protein–protein interaction networks. SVM classifiers with the maximum area under the curve were based on 30 and 15 genes in the brown and red modules, respectively. The clinical significance of the 45 hub genes was analyzed. Of the 45 genes, 17 were found to be significantly correlated with survival time. Finally, 5/17 genes, including ADAP2 (P = 0.0094), LCP2 (P = 0.013), ARHGAP25 (P = 0.0049), CD53 (P = 0.016), and TLR7 (P = 0.04) were significantly correlated with the metastatic phenotype. In vitro verification, western blotting, wound healing analyses, transwell invasion assays, proliferation assays, and colony formation assays indicated that ARHGAP25 promoted OS cell migration, invasion, proliferation, and epithelial–mesenchymal transition.ConclusionWe identified five genes, namely ADAP2, LCP2, ARHGAP25, CD53, and TLR7, as candidate biomarkers for the prediction of OS metastasis; ARHGAP25 inhibits MG63 OS cell growth, migration, and invasion in vitro, indicating that ARHGAP25 can serve as a promising specific and prognostic biomarker for OS metastasis.

Highlights

  • Osteosarcoma (OS) metastasis is the most common cause of cancer-related mortality, no sufficient clinical biomarkers have been identified

  • By using summary preservation statistics, we evaluated whether the co-expression modules were stable from the training dataset (GSE33382 and GSE21257) to The Cancer Genome Atlas (TCGA) test dataset

  • We found that the CD53 mRNA expression level was lower in metastatic OS samples, which is in accordance with the decreased CD53 expression in high-metastasis breast cancer in a previous study [31]

Read more

Summary

Introduction

Osteosarcoma (OS) metastasis is the most common cause of cancer-related mortality, no sufficient clinical biomarkers have been identified. We identified five genes to help predict metastasis at diagnosis. OS metastasis is the most common cause of cancer-related mortality. Several molecular mechanisms have been identified to play a role in the OS metastasis cascade, such as the Wnt/β-catenin pathway [4, 5], PI3K/Akt/mTOR [6] and Notch signaling [7]. Many genes have been identified as potential biomarkers for the prediction and treatment of OS metastasis [8,9,10]. The mechanism underlying OS metastasis remains unclear. A better understanding of the mechanism of OS metastasis is urgently required to identify more effective and specific biomarkers for early prediction, survival assessment, and treatment

Objectives
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.